Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-180291 SCHEMBL28137 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Ifetroban SCHEMBL30218601 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL9589119 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL29502980 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL28136 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| SCHEMBL8918962 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Ifetroban SCHEMBL16212975 | 0.99 | TBXA2R (0.98) | TBXA2R | |
| Bms-180291 SCHEMBL16212977 | 0.99 | TBXA2R (0.98) | TBXA2R | |
| SCHEMBL8918573 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL362595 | 0.99 | TBXA2R (0.98) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5123 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| US-12527839-B2 | Treatments for systemic sclerosis | ACCELERON PHARMA INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | claimed |
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-05-15 | — | — | US | claimed |
| US-20250144079-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2025-05-08 | — | — | US | claimed |
| US-20250114334-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2025-04-10 | — | — | US | claimed |
| CN-119522896-A | Cell stabilizer and application thereof | 广州市雷德生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20250049764-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | CUMBERLAND PHARMACEUTICALS INC. | 2025-02-13 | — | — | US | claimed |
| EP-4482481-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | Som Innovation Biotech, S.L. (ES) | 2025-01-01 | — | — | EP | claimed |
| US-12161632-B2 | Compositions and methods of treating cardiac fibrosis with ifetroban | CUMBERLAND PHARMACEUTICALS INC. (US) | 2024-12-10 | — | — | US | claimed |
| EP-1156803-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | claimed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2000047207-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-17 | — | — | WO | claimed |
| US-5605917-A | ADMINISTERING A THROMBOXANE A2 RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-02-25 | — | — | US | claimed |
| WO-1996017606-A1 | USE OF INFLAMMATORY MODULATORS IN THE TREATMENT OF CHRONIC OR RECALCITRANT SKIN DAMAGE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-06-13 | — | — | WO | claimed |
| US-5506248-A | SALT OF IFETROBAN AND ONE OR MORE BASIFYING AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-09 | — | — | US | claimed |
| CN-1118254-A | Pharmaceutical compositions having good dissolution properties | BRISTOL MYERS SQIBB COMPANY (US) | 1996-03-13 | — | — | CN | claimed |
| EP-0638310-A1 | Pharmaceutical compositions containing ifetroban | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-15 | — | — | EP | claimed |